Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model. [electronic resource]
Producer: 20070509Description: 227-32 p. digitalISSN:- 1077-4114
- Adolescent
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antiviral Agents -- adverse effects
- Bone Marrow Transplantation
- Child
- Child, Preschool
- Decision Support Techniques
- Disease-Free Survival
- Female
- Humans
- Immunocompromised Host
- Infant
- Infant, Newborn
- Male
- Palivizumab
- Respiratory Syncytial Virus Infections -- mortality
- Respiratory Syncytial Virus, Human
- Survival Rate
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.